Breadcrumb

What's New at the RI-MUHC ?

LSD, a future antianxiety pill?

A new study by Dr. Gabriella Gobbi reveals the neurobiological mechanisms by which LSD could relieve anxiety

The sky is not the limit

Researchers look to team of astronauts to help answer important questions about chronic pain and sleep

BCG vaccine provides protection against influenza virus but not SARS-CoV-2

A new study led by RI-MUHC researchers reveals that the 100-year-old tuberculosis vaccine known as..

What’s the signature of a healthy heart?

Instead of treating the “average person,” the Courtois Cardiovascular Signature Program aims to treat every person as a unique individual

COVID-19: A close look at vaccine strategies used with older people in Quebec

A new study determines the maximum recommended interval between the first and second doses of mRNA...

CTN study tests new drug for the first time in people living with HIV

Postdoc Léna Royston aims to understand how cytomegalovirus infection can increase inflammation and cause health issues

RI-MUHC team uncovers new mechanism of inflammation in muscular dystrophy

A new study reveals how signals sent from damaged muscles to the bone marrow can induce long-lasting...

A clear picture of the cost and efficacy of COVID-19 outpatient treatments

In a new study, RI-MUHC researchers have assessed all available outpatient therapies for COVID-19 to facilitate...

Unraveling the complexity of vitamin B12 diseases

Nature Communications study has implications for treatment of patients and genetic counselling

Learn more about the RI-MUHC